Cancer drug developer Antisoma (LSE:ASM) announces that it has reopened a U.S. phase I trial of its aptamer drug AS1411 following the presentation of promising data at this year’s American Society of Clinical Oncology meeting. The study is now enrolling patients with renal and non-small cell lung cancers. Signs of anti-cancer activity were seen in all of the three renal cancer patients included in the original trial, and Antisoma has recently been granted U.S. orphan drug status for AS1411 in renal cancer.